Randomised controlled trial · 2006
Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire
Arafa M, Shamloul R (2006). Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. International Journal of Impotence Research. doi:10.1038/sj.ijir.3901469
In a single-blind crossover trial of sertraline versus placebo for PE, most men improved on sertraline, but 66 of 100 men followed up (66%) relapsed within 6 months of stopping it.
Summary
This single-blinded, randomised, placebo-controlled crossover study tested sertraline, a selective serotonin reuptake inhibitor (SSRI), in men with premature ejaculation (PE). It enrolled 147 men, randomised into two groups that received sertraline and placebo in turn for four weeks each. Results were measured with the Arabic Index of Premature Ejaculation, a validated questionnaire.
Most men experienced a significant improvement in their questionnaire score while taking sertraline, and the drug was generally well tolerated. Of the 100 men available for follow-up after treatment ended, 66 (66%) had a relapse of PE within six months of stopping sertraline.
Limitations
Only the participants, not the researchers, were blinded, treatment periods were short, and outcomes were measured by questionnaire rather than stopwatch. The abstract reports inconsistent denominators for the response rate, and follow-up was incomplete.
What it means for you
An SSRI can delay ejaculation while you take it, but in this study two out of three men were back where they started within six months of stopping. That is normal for this kind of medicine, and it is why skills that last, such as arousal awareness and pelvic floor control, are worth building alongside or after it.